Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: Masimo/Kontron

This article was originally published in The Gray Sheet

Executive Summary

Masimo/Kontron: Enter "joint product development and licensing partnership under which Kontron will integrate Masimo's proprietary pulse oximetry signal processing and sensor technology into" Kontron's products. Kontron will adopt Masimo's Signal Extraction Technology, which "reduces measurement problems encountered when pulse oximetry is used during transport, in emergency departments, neonatal ICU's, general wards and in all applications in which high motion and/or low perfusion issues exist." Commenting on the deal, Kontron President Lee Smith said the technology will enable Kontron to "significantly enhance" its noninvasive pulse oximetry "capabilities as compared to existing technology"...

You may also be interested in...



Australia Looking Into In-Vitro Self-Test Deregulation

In-vitro self-tests for influenza and sexually transmitted diseases as well as direct-to-consumer genetic tests are on the agenda for deregulation in Australia. 

ConMed’s ‘No Smoking’ Drive Has Multiple Benefits In General Surgery

ConMed Corp. is company of two halves  ̶  general surgery and orthopedics – and is readying itself for a renewed assault on these two markets on the back of a technology pipeline, targeted acquisitions and a new growth-winning culture, says CFO Todd Garner.

Behave, Pharma: Why Culture Is Top Of The List

Drug pricing and access issues expose the pharmaceutical sector especially acutely to calls for companies to meet ethical and social goals, alongside commercial ones. Digital is up-ending pharma’s processes, its workplaces and its consumers. R&D productivity is spluttering. Amid this turmoil, CEOs highlight company culture – the way an organization behaves – as a crucial ingredient for success. But what is a “right” culture? Organizational culture is neither static nor singular. It is continuously influenced by acquisitions, markets, new technologies and new generations. And pharma’s history suggests that culture change cannot happen without sufficient people change.

UsernamePublicRestriction

Register

MT005495

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel